BioLife Solutions (BLFS) Aandeel Koers
BioLife Solutions Koers
De omzet is de afgelopen 19 jaar met 30,6% per jaar gegroeid tot 96,21 Miljoen USD. De nettowinstmarge van BioLife Solutions ligt op -12,6% en is ten opzichte van -7,5% enkele jaren eerder gedaald. Analisten hanteren een mediaan koersdoel van 31,00 USD — dat impliceert 19,7% onder de huidige koers. Van de 15 analisten geven 7 het aandeel een koopadvies — per saldo een Houden-consensus.
BioLife Solutions aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
BioLife Solutions bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over BioLife Solutions
BioLife Solutions Inc is a biotech company specializing in developing, manufacturing, and marketing cell and tissue preservation solutions. Their business model revolves around providing innovative products that enhance the effectiveness of biological materials storage and transportation. BioLife Solutions offers a comprehensive portfolio of biopreservation media, enabling improved cell therapies, vaccines, and drug discovery research. By supplying high-quality, proprietary products, BioLife Solutions caters to the needs of various sectors, including regenerative medicine, biobanking, and pharmaceuticals. Through their advanced technologies and solutions, BioLife Solutions Inc aims to support the success of customers in preserving and delivering vital biological materials.
BioLife Solutions Inc is primarily active in the biotechnology industry.
The main competitors of BioLife Solutions Inc in the market include companies such as Thermo Fisher Scientific Inc, Merck KGaA, Teva Pharmaceutical Industries Ltd, and Zimmer Biomet Holdings Inc.
BioLife Solutions Inc, a leading developer and supplier of biopreservation tools for cells and tissues, has a rich history and background. Founded in 1998, the company has been dedicated to improving the quality and extending the shelf life of biological materials. BioLife Solutions Inc specializes in innovative solutions that enable the effective storage, freezing, and transportation of biological samples used in research, clinical trials, and regenerative medicine. With a strong focus on quality and customer satisfaction, BioLife Solutions Inc has become a trusted partner for biotech and pharmaceutical companies worldwide. The company's commitment to continuous innovation and collaboration underscores its position as a leader in the biopreservation industry.
BioLife Solutions Inc. has accomplished several significant milestones. The company has expanded its product portfolio, offering a comprehensive range of innovative biopreservation solutions for cells, tissues, and organs. It has successfully developed and commercialized proprietary technologies to enhance the shelf life and improve the efficacy of biological materials. Furthermore, BioLife Solutions has achieved consistent revenue growth and profitability, demonstrating its strong market presence and customer satisfaction. The company has also forged strategic partnerships with leading organizations, leveraging its expertise to develop cutting-edge biopreservation systems. These achievements highlight BioLife Solutions Inc.'s commitment to advancing biological storage and transportation solutions while delivering value to its customers and stakeholders.
BioLife Solutions Inc is primarily present in the United States. With its headquarters located in Bothell, Washington, the company operates throughout the country. As a leading provider of biopreservation tools and services, BioLife Solutions Inc serves a diverse customer base in the life sciences industry across various states and regions in the United States. The company focuses on supplying innovative bioprocessing solutions and ensuring the quality and preservation of biological materials, such as cells, tissues, and organs, for medical research and therapeutic purposes.
BioLife Solutions Inc is a leading provider of biopreservation tools and services. The company's values center around innovation, quality, and customer satisfaction. With a strong commitment to advancing regenerative medicine and improving patient outcomes, BioLife Solutions Inc focuses on delivering best-in-class biopreservation solutions to its clients. The corporate philosophy of the company revolves around continuous improvement and collaboration with customers, researchers, and industry partners. By offering a wide range of high-performance biopreservation products and leveraging its expertise in cell and tissue preservation, BioLife Solutions Inc strives to contribute to the success and progress of the life sciences industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 31,00 USD voor het aandeel BioLife Solutions (mediaan: 31,00 USD), oftewel -19,7 % ten opzichte van de laatste koers. De consensus is gebaseerd op 15 analistenratings.
15 analisten beoordelen het aandeel BioLife Solutions momenteel: 7 adviseren kopen, 8 houden en 0 verkopen. Voor 2026 verwachten analisten dat BioLife Solutions een omzet van 114,72 Miljoen USD en winst per aandeel van 0,59 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel BioLife Solutions op 34,40 EUR (38,61 USD).
Het aandeel BioLife Solutions (BLFS) is genoteerd aan 3 beurzen, waaronder: NASDAQ (BLFS), Frankfurt (BJX1.F), Düsseldorf (BJX1.DU).
BioLife Solutions Inc is a company specializing in the production of high-quality biological solutions for customers in the biopharmaceutical and biotechnology industries. The business is divided into two main divisions: BioLife Solutions and Astero Bio. BioLife Solutions focuses on manufacturing proprietary biological solutions for customers in the biopharmaceutical and biotechnology industries, which are used for the stabilization and maintenance of the quality of biological materials such as cells, tissues, and organs. Products include CryoStor, a clinically tested cell cryopreservation solution, and HypoThermosol, a patented cell culture medium specifically designed for the storage and transportation of cell and tissue samples. BioLife Solutions also offers custom formulations for specific applications. The second division, Astero Bio, specializes in the development and manufacturing of temperature control devices for biological storage. The Astero portfolio includes cryogenic storage systems that maintain the quality and integrity of biological samples during storage. Astero Bio also offers biological safety cabinets for laboratories handling pathogenic or toxin-producing organisms. BioLife Solutions and Astero Bio work together to provide their customers with a complete solution for the stabilization and protection of biological materials. The products and solutions of BioLife Solutions and Astero Bio are tailored to meet customer requirements and comply with international standards such as Good Manufacturing Practice (GMP) and the International Organization for Standardization (ISO). BioLife Solutions' business model is based on a value chain, starting with the research and development of new biological solutions and extending to the production and market introduction of these solutions. The solutions and products of BioLife Solutions and Astero Bio are designed to meet customer needs and aim to enhance the efficiency and profitability of companies in the biopharmaceutical and biotechnology industries. BioLife Solutions and Astero Bio have a strong position in the global market for biological solutions, and their products are used by leading companies and institutions worldwide. The company has a strong track record and is committed to further growth and expanding its technological capabilities in the future. The products and solutions of BioLife Solutions and Astero Bio contribute to the progress and development in biotechnology, ultimately improving the quality of life for patients worldwide.
De verwachte omzet van BioLife Solutions bedraagt 114,72 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van BioLife Solutions bedraagt 28,65 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van BioLife Solutions bedraagt momenteel 65,55. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het BioLife Solutions-aandeel in te schatten.
De koers-omzetverhouding (P/S) van BioLife Solutions bedraagt momenteel 16,37. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het BioLife Solutions-aandeel.
De Eulerpool Kwaliteitsscore voor BioLife Solutions is 2/10.
De ISIN van BioLife Solutions is US09062W2044. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van BioLife Solutions is A1XCF2. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van BioLife Solutions is BLFS. Onder dit beurstickersymbool wordt het BioLife Solutions-aandeel op de beurs verhandeld.
BioLife Solutions aandeel
BioLife Solutions Peer Group
BioLife Solutions Ticker
BioLife Solutions FIGI
Alle fundamentals en diepgaande analyse van BioLife Solutions
Onze aandelenanalyse van het BioLife Solutions-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van BioLife Solutions. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: